Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients
Copyright © 2022 Elsevier Ltd. All rights reserved..
INTRODUCTION: Identification of tumours harbouring an overall active immune phenotype may help for selecting patients with advanced head and neck squamous cell carcinomas (HNSCC) and non-small cell lung cancer (NSCLC) who may benefit from immunotherapies. Our objective was to develop a reliable and stable scoring system to identify those immunologically active tumours.
METHODS: Using gene expression profiles of 421 HNSCC, we developed a score to identify immunologically active tumours. Validation of the 'HOT' score was done in 40 HNSCC and 992 NSCLC. Stability of the 'HOT' score was tested in paired HNSCC samples from diagnostic biopsies versus surgically resected specimens, untreated versus recurrent samples, and pre-versus post-cetuximab samples in a total of 76 patients. The association between the 'HOT' score with overall survival (OS) and progression-free survival (PFS) was tested in 184 patients with HNSCC or NSCLC treated with PD-1/PD-L1 inhibitors.
RESULTS: A 27-gene expression based 'HOT' score was correlated with: (i) PD-L1 and IDO1 expression, (ii) TCD8 infiltrate and (iii) activation of the IFN-γ pathway. The HOT score concordance when comparing diagnostic biopsies and surgically resected specimens was higher than in untreated samples versus recurrent or pre-versus post-cetuximab samples. In 102 and 82 patients with HNSCC or NSCLC treated with PD-1/PD-L1 inhibitors, the HOT score was associated with an improved OS and PFS in multivariate analysis.
CONCLUSION: The 'HOT' score is a simple and robust approach to identify real-world patients with HNSCC and NSCLC immunologically active tumours who may benefit from PD-1/PD-L1 inhibitors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:174 |
|---|---|
| Enthalten in: |
European journal of cancer (Oxford, England : 1990) - 174(2022) vom: 18. Okt., Seite 287-298 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Foy, Jean-Philippe [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.09.2022 Date Revised 08.11.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejca.2022.06.034 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM345559002 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM345559002 | ||
| 003 | DE-627 | ||
| 005 | 20231226025331.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2022.06.034 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1151.xml |
| 035 | |a (DE-627)NLM345559002 | ||
| 035 | |a (NLM)36038492 | ||
| 035 | |a (PII)S0959-8049(22)00385-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Foy, Jean-Philippe |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.09.2022 | ||
| 500 | |a Date Revised 08.11.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Ltd. All rights reserved. | ||
| 520 | |a INTRODUCTION: Identification of tumours harbouring an overall active immune phenotype may help for selecting patients with advanced head and neck squamous cell carcinomas (HNSCC) and non-small cell lung cancer (NSCLC) who may benefit from immunotherapies. Our objective was to develop a reliable and stable scoring system to identify those immunologically active tumours | ||
| 520 | |a METHODS: Using gene expression profiles of 421 HNSCC, we developed a score to identify immunologically active tumours. Validation of the 'HOT' score was done in 40 HNSCC and 992 NSCLC. Stability of the 'HOT' score was tested in paired HNSCC samples from diagnostic biopsies versus surgically resected specimens, untreated versus recurrent samples, and pre-versus post-cetuximab samples in a total of 76 patients. The association between the 'HOT' score with overall survival (OS) and progression-free survival (PFS) was tested in 184 patients with HNSCC or NSCLC treated with PD-1/PD-L1 inhibitors | ||
| 520 | |a RESULTS: A 27-gene expression based 'HOT' score was correlated with: (i) PD-L1 and IDO1 expression, (ii) TCD8 infiltrate and (iii) activation of the IFN-γ pathway. The HOT score concordance when comparing diagnostic biopsies and surgically resected specimens was higher than in untreated samples versus recurrent or pre-versus post-cetuximab samples. In 102 and 82 patients with HNSCC or NSCLC treated with PD-1/PD-L1 inhibitors, the HOT score was associated with an improved OS and PFS in multivariate analysis | ||
| 520 | |a CONCLUSION: The 'HOT' score is a simple and robust approach to identify real-world patients with HNSCC and NSCLC immunologically active tumours who may benefit from PD-1/PD-L1 inhibitors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Biomarker | |
| 650 | 4 | |a Head and neck cancer | |
| 650 | 4 | |a Immune microenvironment | |
| 650 | 4 | |a Immunologically hot tumours | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Non-small cell lung cancer | |
| 650 | 7 | |a B7-H1 Antigen |2 NLM | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 650 | 7 | |a Programmed Cell Death 1 Receptor |2 NLM | |
| 650 | 7 | |a Cetuximab |2 NLM | |
| 650 | 7 | |a PQX0D8J21J |2 NLM | |
| 700 | 1 | |a Karabajakian, Andy |e verfasserin |4 aut | |
| 700 | 1 | |a Ortiz-Cuaran, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Boussageon, Maxime |e verfasserin |4 aut | |
| 700 | 1 | |a Michon, Lucas |e verfasserin |4 aut | |
| 700 | 1 | |a Bouaoud, Jebrane |e verfasserin |4 aut | |
| 700 | 1 | |a Fekiri, Dorssafe |e verfasserin |4 aut | |
| 700 | 1 | |a Robert, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Baffert, Kim-Arthur |e verfasserin |4 aut | |
| 700 | 1 | |a Hervé, Geneviève |e verfasserin |4 aut | |
| 700 | 1 | |a Quilhot, Pauline |e verfasserin |4 aut | |
| 700 | 1 | |a Attignon, Valéry |e verfasserin |4 aut | |
| 700 | 1 | |a Girod, Angélique |e verfasserin |4 aut | |
| 700 | 1 | |a Chaine, André |e verfasserin |4 aut | |
| 700 | 1 | |a Benassarou, Mourad |e verfasserin |4 aut | |
| 700 | 1 | |a Zrounba, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Caux, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Ghiringhelli, François |e verfasserin |4 aut | |
| 700 | 1 | |a Lantuejoul, Sylvie |e verfasserin |4 aut | |
| 700 | 1 | |a Crozes, Carole |e verfasserin |4 aut | |
| 700 | 1 | |a Brochériou, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Pérol, Maurice |e verfasserin |4 aut | |
| 700 | 1 | |a Fayette, Jérôme |e verfasserin |4 aut | |
| 700 | 1 | |a Bertolus, Chloé |e verfasserin |4 aut | |
| 700 | 1 | |a Saintigny, Pierre |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer (Oxford, England : 1990) |d 1991 |g 174(2022) vom: 18. Okt., Seite 287-298 |w (DE-627)NLM012602779 |x 1879-0852 |7 nnns |
| 773 | 1 | 8 | |g volume:174 |g year:2022 |g day:18 |g month:10 |g pages:287-298 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejca.2022.06.034 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 174 |j 2022 |b 18 |c 10 |h 287-298 | ||